Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
ASCO 2017 - Chronic Lymphocytic Leukemia
ASCO 2017 - Chronic Lymphocytic Leukemia
Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
COSMOS: A 2-Cohort, Phase 2 Study of MOR208 plus Idelalisib or Venetoclax in Patients with R/R CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
,
Conference Correspondent
Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
,
Conference Correspondent
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
,
Conference Correspondent
Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia
,
Conference Correspondent
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Read More
1
2
Page 2 of 2
Results 11 - 16 of 16